All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub spoke to Marion Subklewe, LMU, Munich, DE. We asked, What are the best strategies for long-term management of hematotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy?
What are the best strategies for long-term management of hematotoxicity associated with CAR-T?
Subklewe begins by outlining findings on the high number of patients presenting with neutropenia and cytopenia post CAR-T. She goes on to identify three clinical phenotypes of neutropenia and their implications. Subklewe explains a scoring system predicting hematotoxicity, which can support risk stratification. She discusses prophylaxis regimens including aciclovir, cotrimoxazole, G-CSF immunoglobulin, and antifungals. Finally, she highlights the importance of monitoring patients after CAR-T.
Assist. Prof. Saar Gill | 2017 ASCO Annual Meeting | Results of using the combination of CD19 CAR-T cells and ibrutinib in CLL patients
Prof. Saar Gill on combining CD19 CAR-T cell therapy and ibrutinib in Chronic Lymphocytic Leukemia patients
Will CAR T-cell therapy change the treatment landscape for MCL?
During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Marion Subklewe, Ludwig-Maximilians-Universität München, Munich, DE. We asked, Will CAR T-cell therapy change the...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox